不久前，Science公布了2022年度十大科學突破，RSV疫苗的突破進展成功入選。呼吸道合胞病毒（Respiratory Syncytial Virus, RSV）作為引起急性下呼吸道感染（ALRTIs）的主要原因之一，每年導致全球約3.31億人發生呼吸道感染。然而，就是這樣一個常見且早已被發現的呼吸道病毒，其疫苗的研發卻十分坎坷，以至于至今仍無一款成熟的RSV疫苗問世。

此前的數十年間，科學家們不曾停止對于RSV疫苗的研究與開發，但均以失敗告終。究其原因，可能是因為RSV病毒結構的特殊性。病毒表面的融合蛋白（fusion protein , F）和粘附蛋白（attachment protein, G）因在病毒入侵過程中的關鍵作用成為病毒研究的理想靶點，而其中G蛋白變異較多相對不穩定，F蛋白也存在Pre到Post構象轉變影響其穩定性。

RSV F蛋白融合前及融合后構象

為了克服這一障礙，科學家們對RSV F蛋白的蛋白結構及其抗體進行了研究，發現該蛋白表面至少存在7個完全不同的抗原表位，并成功篩選到可以與不同表位結合的抗體，分別為φ site_D25/5C4/AM22，I site_131-2A/2F，II site_motavizumab/palivizumab，III site_MPE8，IV site_101F/mAb19，V site_hRSV90。其中識別IV表位的101F、識別II表位的palivizumab和識別I表位的131-2A抗體可以同時識別F蛋白的pre和post構象，識別φ表位的D25抗體只與Pre構象的F蛋白發生結合，識別III表位的MPE8抗體則偏好識別Pre構象，與Post構象具有較弱的結合活性[1]。2010年，Kwakkenbos研究團隊篩選獲得單克隆抗體AM14，其識別的抗原表位位于F-pre蛋白近赤道區域，橫跨兩個單體，可特異性識別F-pre三聚體結構，且被證明與此前中和效果最佳的D25抗體具有相似的中和活性和更快的動力學性質^[2,3]。

RSV-F蛋白抗原表位及抗體結合情況^[2,3]

ACROBiosystems，真正的蛋白結構專家?

基于成熟的蛋白表達平臺與結構驗證方案，在對RSV病毒進行充分調研后，我們開發了RSV病毒研究關鍵的G蛋白與不同構象的F蛋白，并從上述抗體中選擇了代表性抗體對所表達的Pre及Post構象F蛋白進行驗證，力求為廣大客戶提供真正的Pre & Post RSV-F蛋白！

驗證數據

★ 純度經SDS-PAGE驗證>95%，經SEC-MALS驗證>90%。

The purity of HRSV (A) Fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H7) is greater than 95% verified by SDS-PAGE and more than 90% verified by SEC-MALS.

★ RSV Pre-F蛋白(Cat. No. RSF-V52H7)與Post-F蛋白(Cat. No. RSF-V52H6)和抗體101F、5C4、AM14、131-2A、D25結合活性經ELISA驗證，與文獻結果一致。

1

Immobilized HRSV (A) Post-fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H6) and HRSV (A) Pre-fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H7) at 1 μg/mL (100 μL/well) can bind Anti-Fusion glycoprotein F0 Antibody, Mouse IgG2a (101F) with a linear range of 0.1-4 ng/mL (QC tested).

Immobilized HRSV (A) Pre-fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H7) at 1 μg/mL (100 μL/well) can bind Recombinant Mouse Anti-RSV F Antibody (5C4) with a linear range of 0.004-0.25 μg/mL. HRSV (A) Post-fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H6) is verified not recoginized by Recombinant Mouse Anti-RSV F Antibody (5C4) (Routinely tested).

Immobilized HRSV (A) Pre-fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H7) at 1 μg/mL (100 μL/well) can bind Recombinant Human Anti-RSV Antibody (AM14) with a linear range of 0.004-0.25 μg/mL. HRSV (A) Post-fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H6) is verified not recognized by Recombinant Human Anti-RSV Antibody (AM14) (QC tested).

Immobilized HRSV (A) Post-fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H6) and HRSV (A) Pre-fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H7) at 1 μg/mL (100 μL/well) can bind Anti-RSV Fusion Protein Antibody (131-2A) with a linear range of 0.1-1 ng/mL . (Routinely tested).

Immobilized HRSV (A) Pre-fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H7) at 1 μg/mL (100 μL/well) can bind Recombinant Human Anti-RSV Antibody (D25) with a linear range of 0.1-2 ng/mL. HRSV (A) Post-fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H6) is verified not recoginized by Recombinant Human Anti-RSV Antibody (D25) in low concentration (Routinely tested).

ACROBiosystems

inquiry@acrobiosystems.com

15117918562

（備注：姓名+公司）

參考文獻：

1. McLellan JS, Chen M, Leung S, et al. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science. 2013;340(6136):1113-1117. doi:10.1126/science.1234914

2. McLellan, J. S., Chen, M., Leung, S., Graepel, K. W., Du, X., Yang, Y., Zhou, T., Baxa, U., Yasuda, E., Beaumont, T., Kumar, A., Modjarrad, K., Zheng, Z., Zhao, M., Xia, N., Kwong, P. D., & Graham, B. S. (2013). Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science, 340(6136), 1113–1117. https://doi.org/10.1126/SCIENCE.1234914/SUPPL_FILE/MCLELLAN.SM.PDF

3. Gilman MSA, Moin SM, Mas V, Chen M, Patel NK, et al. (2015) Characterization of a Prefusion-Specific Antibody That Recognizes a Quaternary, Cleavage-Dependent Epitope on the RSV Fusion Glycoprotein. PLOS Pathogens 11(7): e1005035. https://doi.org/10.1371/journal.ppat.1005035